TAKEDA PHARMACEUTIC-SP ADR (TAK)

US8740602052 - ADR

13.22  -0.09 (-0.68%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (5/17/2024, 7:04:00 PM)

13.22

-0.09 (-0.68%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap41.48B
Shares
PE44.07
Fwd PE26.06
Dividend Yield4.74%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TAK Daily chart

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 49,095 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Company Info

TAKEDA PHARMACEUTIC-SP ADR

4F, 2-1-1, Nihombashihon-cho

Chuo-Ku TOKYO-TO 103-8668

P: 81332782111

CEO: Christophe Weber

Employees: 49095

Website: https://www.takeda.com/

TAK News

News Image2 days ago - Takeda Canada, Inc.Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection

/CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a...

News Image4 days ago - Takeda Pharmaceutical Company LimitedTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
News Image5 days ago - InvestorPlaceWhy Is AC Immune (ACIU) Stock Up 45% Today?

AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.

News Image5 days ago - Takeda Pharmaceutical Company LimitedAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
News Image8 days ago - Investor's Business DailyCatalyst's New CEO Has Big Ideas For The Small Biotech

Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.

News Image9 days ago - InvestorPlaceTAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023

Takeda Pharmaceutical just reported results for the fourth quarter of 2023.

TAK Twits

Here you can normally see the latest stock twits on TAK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example